Diabetic Neuropathy - Pipeline Insight, 2024

This “Diabetic Neuropathy- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diabetic Neuropathy: Understanding

Diabetic Neuropathy: Overview

Diabetic neuropathy is a type of nerve damage that occurs in individuals with diabetes. It primarily affects those with poorly managed blood sugar levels over an extended period. The condition commonly manifests in the peripheral nerves, which control sensation and movement in the limbs. There are several types of diabetic neuropathy, including peripheral neuropathy (affecting the feet and hands), autonomic neuropathy (affecting internal organs), proximal neuropathy (affecting thighs, hips, or buttocks), and focal neuropathy (affecting a specific nerve).

Signs and symptoms of diabetic neuropathy can vary depending on the type and severity of nerve damage. Peripheral neuropathy often presents with tingling, numbness, or pain in the extremities, which can progress to loss of sensation and difficulty coordinating movements. Autonomic neuropathy may lead to digestive issues, urinary problems, sexual dysfunction, and cardiovascular abnormalities. Proximal neuropathy typically causes pain in the thighs, hips, or buttocks, while focal neuropathy results in sudden, localized weakness or pain in a specific nerve.

The exact causes of diabetic neuropathy are not fully understood, but prolonged exposure to high blood sugar levels is a significant contributing factor. High glucose levels can damage blood vessels that supply oxygen and essential nutrients to nerves, leading to their deterioration. Additionally, other factors such as inflammation, genetic predisposition, and lifestyle factors like smoking and excessive alcohol consumption can exacerbate nerve damage in individuals with diabetes. The pathophysiology involves a complex interplay of metabolic, vascular, and inflammatory mechanisms that ultimately result in nerve dysfunction.

Diagnosis of diabetic neuropathy typically involves a combination of medical history review, physical examination, and various tests such as nerve conduction studies, electromyography, and sensory exams. Blood tests to assess glucose levels and other metabolic markers may also be conducted to evaluate the severity and progression of neuropathy. Treatment focuses on managing symptoms, slowing the progression of nerve damage, and preventing complications. This often includes maintaining tight control of blood sugar levels through diet, exercise, and medication. Additionally, pain management techniques such as medications, physical therapy, and alternative therapies like acupuncture may be recommended to alleviate discomfort and improve quality of life for individuals with diabetic neuropathy.  

"Diabetic Neuropathy- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Neuropathy pipeline landscape is provided which includes the disease overview and Diabetic Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Neuropathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Neuropathy.

Diabetic Neuropathy Emerging Drugs Chapters

This segment of the Diabetic Neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Neuropathy Emerging Drugs

SER 150: Serodus

SER150 is an anti-inflammatory compound with a novel mode of action both inhibiting thromboxane synthase as well as blocking the thromboxane (TP) receptor. SER150 is expected to specifically inhibit the inflammatory processes in the renal arterioles and glomeruli and reduce the progression of renal impairment whereby the amount of protein excreted in urine will decrease. Treatment with ACE-inhibitor antihypertensives is the golden standard of treatment of diabetic nephropathy but that treatment does not inhibit the fundamental causes of renal damage nor does it cure the disease. Since the inflammation is a progressive process causing loss of the renal function, SER150 could potentially become a very significant combination (add-on) therapy as standard daily treatment in patients with diabetic nephropathy. It is expected that SER150 treatment delays progression or even prevents development of the disease. Consequently, SER150 has a blockbuster market potential. Currently, the drug is in Phase II/III stage of its development for the treatment of diabetic neuropathy.

LMB-763: Novartis

Nidufexor is a novel investigational compound with partial FXR agonistic activity in vitro and FXR-dependent gene modulation in vivo. Nidufexor has advanced to Phase II human clinical trials in patients with NASH and diabetic nephropathy. The drug candidate is farnesoid X-activated receptor agonists. Currently, the drug is in Phase II stage of its development for the treatment of diabetic neuropathy.

CU01: Curacle Co., Ltd

CU01 Dimethyl fumarate (DMF). CU01 has excellent therapeutic effects in reducing renal fibrosis by activating Nrf2 to inhibit TGF-β/SMAD signaling and the expression of extracellular matrix. The drug candidate is applicable only for early symptom relief. Not applicable to patients with ESRD (End Stage Renal Disease).There is an unmet medical need for cardiovascular protection agents. Currently, the drug is in Phase II stage of its development for the treatment of diabetic neuropathy.

Diabetic Neuropathy: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Neuropathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Diabetic Neuropathy

• There are approx. 20+ key companies which are developing the therapies for Diabetic Neuropathy. The companies which have their Diabetic Neuropathy drug candidates in the most advanced stage, i.e. phase II/III include, Serodus.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Diabetic Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Neuropathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Neuropathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Neuropathy drugs.

Diabetic Neuropathy Report Insights

• Diabetic Neuropathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Neuropathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Neuropathy drugs?
• How many Diabetic Neuropathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Neuropathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Neuropathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Neuropathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Serodus
• Novartis
• Curacle Co., Ltd
• Sonnet BioTherapeutics, Inc.
• Teijin America, Inc.
• Shanghai Pharmaceuticals Holding Co., Ltd
• ChemoCentryx
• Roche
• Cyclerion Therapeutics
• Inversago Pharma Inc
• Sunshine Lake Pharma Co., Ltd.
• Goldfinch Bio
• Cosette Pharmaceuticals
• Boehringer Ingelheim
• Chinook Therapeutics

Key Products

• SER 150
• LMB-763
• CU01
• SON 080
• TMX-049
• SPH3127
• CCX140-B
• Pirfenidone
• Praliciguat
• INV 202
• HEC73077
• GFB-887
• Bremelanotide
• Avenciguat
• Atrasentan

This product will be delivered within 1-3 business days.